Aug 31, 2021 / 06:30AM GMT
Per Walday - PCI Biotech Holding ASA - CEO
Good morning, and welcome to the interim report for second quarter in first half of 2021 for PCI Biotech. My name is Per Walday, I'm the CEO of PCI Biotech, and I have with me Ronny Skuggedal, who is the CFO of PCI Biotech.
First, please pay attention to this important notice. We have in this conference now webcast, but also a phone line, and you have all the information on this slide for how you can post questions through the webcast or through the phone live after the presentation.
I will start the presentation with going through PCI Biotech, the company in general and the technology specifically, and then review each of the 3 different programs a bit more in detail before we go to -- through the financial numbers and the outlook at the end. And then we take questions. I think we start with live questions, and then we will go over to the questions from the webcast at the end.
So first, PCI Biotech. PCI is an oncology-focused pipeline company. We are developing a specific technology, photochemical internalization. We have 3 different
Q2 2021 PCI Biotech Holding ASA Earnings Call Transcript
Mar 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers